SAB Competitors

Stocks . USA . 
Stock . SAB Biotherapeutics
SABSW Stock  USD 0.03  0  7.22%   
SAB Biotherapeutics competes with IMAC Holdings, Nuwellis, Revelation Biosciences, Pasithea Therapeutics, and Dermata Therapeutics; as well as few others. The company classifies itself under Biotechnology sector and is part of Health Care industry. Analyzing SAB Biotherapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of SAB Biotherapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out SAB Biotherapeutics Correlation with its peers.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of SAB Biotherapeutics competition on your existing holdings.
  
Build AI portfolio with SAB Stock
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of SAB Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.0315.74
Details
Intrinsic
Valuation
LowRealHigh
0.000.0315.74
Details

SAB Biotherapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between SAB Biotherapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of SAB and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of SAB Biotherapeutics does not affect the price movement of the other competitor.

High positive correlations

DRMA
+ 0.93
NUWE
REVB
+ 0.91
NUWE
DRMA
+ 0.89
REVB
REVB
+ 0.85
VINC
NUWE
+ 0.8
VINC
DRMA
+ 0.79
VINC
  

High negative correlations

DRMA
- 0.55
BACK
DRMA
- 0.45
KTTA
KTTA
- 0.43
BCTXW
NUWE
- 0.42
BACK
KTTA
- 0.4
NUWE
OCEA
- 0.38
BCTXW

Risk-Adjusted Indicators

There is a big difference between SAB Stock performing well and SAB Biotherapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze SAB Biotherapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VINC  6.89  0.08  0.00  0.20  14.62 
(11.55)
 18.81 
(22.88)
 127.90 
BACK  16.24  4.40  0.20 (0.75) 13.46 
(22.51)
 37.80 
(22.27)
 271.43 
BCTXW  7.88  0.59  0.02 (0.22) 11.41 
(8.28)
 19.44 
(16.78)
 44.95 
SYRS  50.63  16.57  0.31  53.98  30.92 
(120.89)
 300.00 
(75.00)
 375.00 
OCEA  50.14  13.91  0.33  1.07  31.41 
(106.77)
 160.00 
(66.67)
 458.33 
NUWE  4.55 (0.88) 0.00 (0.46) 0.00 
 0.00 
 10.66 
(9.26)
 49.33 
REVB  2.87 (0.87) 0.00 (0.28) 0.00 
 0.00 
 5.50 
(7.14)
 19.41 
VRPX  68.78  29.72  0.00  1.32  0.00 
 0.00 
 9.52 
(8.70)
 1,989 
KTTA  7.72  0.98  0.13  0.39  7.80 
(11.48)
 16.67 
(12.50)
 137.41 
DRMA  4.94 (1.01) 0.00 (0.98) 0.00 
 0.00 
 13.85 
(10.23)
 37.70 
All Fundamental Data

SAB Biotherapeutics Competitive Analysis

The better you understand SAB Biotherapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, SAB Biotherapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across SAB Biotherapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SABSW VINC BACK BCTXW SYRS OCEA NUWE REVB VRPX KTTA
 7.22 
 0.03 
SAB
 0.79 
 0.01 
Vincerx
 7.69 
 0.12 
IMAC
 41.95 
 0.03 
BriaCell
 75.00 
 0.0002 
Syros
 73.33 
 0.0004 
Ocean
 3.55 
 1.90 
Nuwellis
 1.10 
 0.90 
Revelation
 0.00 
 0.01 
Virpax
 3.30 
 0.88 
Pasithea
Market Volatility
(90 Days Market Risk)
Out of control
Somewhat reliable
Out of control
Out of control
Out of control
Out of control
Very risky
Slightly risky
Out of control
Out of control
Market Performance
(90 Days Performance)
Mild
Soft
Fair
Weakest
Solid
Solid
Weakest
Weakest
Good
Mild
Odds of Financial Distress
(Probability Of Bankruptcy)
Strong
Risky
Strong
Risky
High
Average
Risky
Risky
Strong
Small
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Sell
Not Available
Not Available
Buy
Buy
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
N/A
7.88
1.18
N/A
6.57
N/A
4.55
0.68
11.84
51.17
Net Asset
44.2 M
8.01 M
1.14 M
21.65 M
168.17 M
902 K
9.86 M
6.62 M
1.56 B
16.06 M
Profit Margin
163.38
N/A
N/A
N/A
N/A
N/A
-2.03
N/A
N/A
N/A
EBITDA
(28.99 M)
(31.46 M)
(5.95 M)
(26.59 M)
(157.19 M)
(957.74 K)
(10.53 M)
(7.95 M)
(12.08 B)
(13.6 M)
Operating Margin
-376.57
N/A
-35.45
N/A
-288.92
N/A
-1.22
N/A
N/A
N/A
Current Valuation
N/A
(4.92 M)
1.48 M
N/A
3.6 M
18.14 M
(1.01 M)
(7.35 M)
(1.21 M)
8.24 M
Price To Book
N/A
0.0317
0.54
N/A
10.65
100.67
0.43
0.49
0.48
1.66
Retained Earnings
(124.17 M)
(189.19 M)
(55.94 M)
(111.76 M)
(722.81 M)
(205.53 M)
(298.79 M)
(40.51 M)
(71.61 B)
(49.58 M)
Current Asset
N/A
N/A
N/A
N/A
85.51 M
N/A
N/A
N/A
N/A
N/A
Beta
0.59
1.76
1.68
1.91
1.31
1.63
-0.17
-0.13
1.42
0.21
Number Of Employees
63
12
2
N/A
68
7
38
8
2
4
Shares Outstanding
N/A
5.23 M
3.37 M
N/A
26.83 M
166.01 M
902.66 K
5.92 M
1.24 M
22.4 M
Cash Flow From Operations
(34.29 M)
(26.13 M)
(2.79 M)
(28.17 M)
(109.71 M)
(4.18 M)
(9.59 M)
(18.32 M)
(16.71 B)
(13.92 M)
Total Debt
4.67 M
5.28 M
1.9 M
4.32 M
62.08 M
16.3 M
545 K
1.91 M
2.47 B
1.28 M
Return On Equity
0.19
-31.36
-3.32
-4.44
-7.77
N/A
-4.67
-1.19
-23.65
-0.9
Return On Asset
-0.23
-1.98
-0.79
-1.62
-0.6
-0.74
-0.93
-0.53
-1.35
-0.54
Number Of Shares Shorted
3.36 K
137.2 K
216.77 K
5.33 K
913.09 K
2.93 M
7.14 K
36.69 K
577.07 K
559.62 K
Book Value Per Share
3.48
0.4
-2.38
5.3
-0.41
-2.8
2.86
3.07
-1.53
1.64
Current Liabilities
N/A
N/A
N/A
N/A
9.57 M
N/A
N/A
N/A
N/A
N/A
Total Asset
44.2 M
8.01 M
1.14 M
21.65 M
168.17 M
902 K
9.86 M
6.62 M
1.56 B
16.06 M
Debt To Equity
N/A
0.052
0.35
N/A
0.5
N/A
0.073
0.009
0.11
0.008
Short Ratio
N/A
0.1
0.29
N/A
0.8
0.05
0.51
0.34
0.04
0.21
Target Price
N/A
200.0
8.25
N/A
8.75
18.5
11.0
21.25
3.0
3.0
Shares Owned By Institutions
N/A
5.25
1.4
N/A
33.97
2.25
4.9
11.9
0.41
22.9
Market Capitalization
N/A
26.17 K
185.12 K
48.08 M
5.37 M
1.93 M
2.2 M
5.36 M
831.85 K
25.09 M
Price To Earning
0.21
N/A
N/A
N/A
-7.92
N/A
N/A
8.69
N/A
N/A
Price To Sales
N/A
N/A
2.57
N/A
13.91
N/A
0.21
2.88
N/A
42.15
Net Income
(34.11 M)
(30.07 M)
(9.42 M)
(26.56 M)
(164.57 M)
(9.48 M)
(11.16 M)
(15.04 M)
(12.07 B)
(13.9 M)
Earnings Per Share
0.29
-5.79
-4.16
N/A
-1.8
-0.34
-250.62
81.25
-71.0
-4.43
Shares Owned By Insiders
N/A
4.11
7.52
N/A
0.73
14.43
1.5
14.24
0.96
1.52
Revenue
1.32 M
N/A
5.2 M
N/A
9.94 M
N/A
8.74 M
N/A
N/A
N/A
Working Capital
15.81 M
1.13 M
(752.65 K)
(3.81 M)
108.3 M
(33.08 M)
6.3 M
4.65 M
(913.76 K)
6.25 M
Cash And Equivalents
N/A
80.86 M
1.61 M
N/A
244.48 M
N/A
12.05 M
3.48 M
26.06 M
47.94 M
Cash Per Share
N/A
3.82
0.06
N/A
12.09
N/A
0.38
0.15
2.22
1.8
Gross Profit
(30.33 M)
N/A
(1.47 M)
N/A
(88.25 M)
N/A
4.97 M
90.91 M
N/A
(2.21 K)
Day Typical Price
0.0281
0.0125
0.11
0.0351
2.0E-4
6.0E-4
1.94
0.91
0.011
0.88
Accumulation Distribution
0.16
N/A
4218.67
75811.24
N/A
0.75
2771.14
4678.41
N/A
8404.52
Market Facilitation Index
0.0047
N/A
0.0
N/A
N/A
9.0E-4
0.0
N/A
N/A
N/A
Daily Balance Of Power
0.4255
(9,223,372,036,855)
(0.50)
(1.06)
(9,223,372,036,855)
(1.22)
(0.44)
(0.25)
0.0
(1.00)
Period Momentum Indicator
0.002
(0.0001)
(0.01)
(0.02)
(0.0006)
(0)
(0.07)
(0.01)
N/A
(0.03)
Rate Of Daily Change
1.07
0.99
0.92
0.58
0.25
0.27
0.96
0.99
1.0
0.97
Day Median Price
0.0274
0.0125
0.11
0.0362
2.0E-4
8.0E-4
1.96
0.91
0.011
0.88
Price Action Indicator
0.0034
(0.00005)
0.005
(0.02)
(0.0003)
(0.0009)
(0.1)
(0.01)
N/A
(0.01)
Coefficient Of Variation
1578.79
10438.43
844.78
2695.07
495.53
568.35
(964.00)
(628.82)
736.43
1306.15
Mean Deviation
9.57
6.89
16.24
7.88
50.63
50.14
4.55
2.87
68.78
7.72
Jensen Alpha
0.9362
0.0758
4.4
0.593
16.57
13.91
(0.88)
(0.87)
29.72
0.9799
Total Risk Alpha
(1.46)
(2.72)
(1.23)
(1.32)
3.77
1.75
(1.75)
(1.23)
(4.82)
(1.43)
Sortino Ratio
0.083
0.0023
0.2048
0.0244
0.309
0.3292
N/A
N/A
N/A
0.1323
Downside Variance
110.97
641.93
331.42
139.02
2850.12
2187.22
N/A
N/A
N/A
89.33
Standard Deviation
15.71
18.5
32.51
10.99
82.33
88.18
6.72
3.87
238.9
17.91
Kurtosis
9.43
18.17
31.16
2.59
6.58
10.15
4.29
0.8038
59.94
27.0
Potential Upside
29.6
18.81
37.8
19.44
300.0
160.0
10.66
5.5
9.52
16.67
Treynor Ratio
2.23
0.2013
(0.75)
(0.22)
53.98
1.07
(0.46)
(0.28)
1.32
0.3934
Maximum Drawdown
105.99
127.9
271.43
44.95
375.0
458.33
49.33
19.41
1989.0
137.41
Variance
246.67
342.43
1057.14
120.7
6779.01
7775.57
45.12
14.95
57073.49
320.61
Market Risk Adjusted Performance
2.24
0.2113
(0.74)
(0.21)
53.99
1.08
(0.45)
(0.27)
1.33
0.4034
Risk Adjusted Performance
0.0543
0.0164
0.0934
0.0356
0.1524
0.1342
(0.06)
(0.10)
0.1059
0.0637
Skewness
2.26
0.9318
4.77
(0.84)
2.45
2.99
0.2524
0.3268
7.62
4.43
Semi Deviation
9.37
14.62
13.46
11.41
30.92
31.41
N/A
N/A
N/A
7.8
Information Ratio
0.0557
0.0031
0.1147
0.0262
0.2003
0.1746
(0.12)
(0.19)
0.1353
0.0699
Value At Risk
(19.08)
(22.88)
(22.27)
(16.78)
(75.00)
(66.67)
(9.26)
(7.14)
(8.70)
(12.50)
Expected Short fall
(14.28)
(11.55)
(22.51)
(8.28)
(120.89)
(106.77)
N/A
N/A
N/A
(11.48)
Downside Deviation
10.53
25.34
18.21
11.79
53.39
46.77
N/A
N/A
N/A
9.45
Semi Variance
87.76
213.79
181.25
130.18
956.18
986.89
N/A
N/A
N/A
60.89

SAB Biotherapeutics Competition Performance Charts

Five steps to successful analysis of SAB Biotherapeutics Competition

SAB Biotherapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by SAB Biotherapeutics in relation to its competition. SAB Biotherapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of SAB Biotherapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact SAB Biotherapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to SAB Biotherapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your SAB Biotherapeutics position

In addition to having SAB Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Recreation Thematic Idea Now

Recreation
Recreation Theme
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY